Vitrebond™ for Tooth Pulp Exposure
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a dental treatment called Vitrebond™ Pulp Protect Liner/Base, designed to protect the inner part of a tooth (the pulp) when exposed. The trial aims to assess the safety and effectiveness of this treatment for individuals with permanent teeth that have pulp exposure due to cavities, injuries, or other accidents. Participants should have at least one permanent tooth requiring a specific dental procedure called direct pulp capping. Individuals with a small pulp exposure in a permanent tooth may be suitable for this study. As an unphased trial, this study offers a unique opportunity to contribute to dental research and potentially benefit from an innovative treatment.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but if you have a history of chronic use of anti-inflammatory, pain, or mind-altering drugs, you may not be eligible to participate.
What prior data suggests that Vitrebond™ Pulp Protect Liner/Base is safe for direct pulp capping?
Research has shown that Vitrebond™ Pulp Protect Liner/Base has been tested for safety in dental work, but not specifically for covering exposed dental pulp. Some sources advise against its direct use on exposed pulp. While the product may be safe for certain dental applications, more research is needed to confirm its safety for this specific purpose.
Studies have not reported any serious side effects, indicating it is generally well-tolerated in dental procedures. However, since this trial tests the product for a new use, its safety for covering exposed pulp remains under investigation. Participants should consider this when deciding whether to join the trial.12345Why are researchers excited about this trial?
Vitrebond™ Pulp Protect Liner/Base is unique because it offers a new approach for direct pulp capping, which is a technique used to protect exposed tooth pulp. Unlike traditional materials like calcium hydroxide or mineral trioxide aggregate, Vitrebond™ uses a light-cured resin-modified glass ionomer that bonds directly to the tooth structure. This bonding capability helps seal the pulp from bacterial infiltration more effectively. Researchers are excited because this could lead to better long-term protection and faster pulp healing.
What evidence suggests that Vitrebond™ might be an effective treatment for tooth pulp exposure?
Research has shown that Vitrebond™, a special dental material, can be effective for direct pulp capping (DPC). It can replace calcium hydroxide, commonly used to protect the soft tissue inside a tooth. In this trial, participants will receive Vitrebond™ Pulp Protect Liner/Base for direct pulp capping. Dentists apply Vitrebond™ to cover and shield the exposed pulp, which can result from cavities or injury. Its effectiveness in maintaining tooth health makes it a promising choice for DPC. Vitrebond™ hardens when exposed to light, simplifying its use for dentists. Overall, it provides a reliable way to protect the inside of a tooth when exposed.678910
Who Is on the Research Team?
Mabi Singh, DMD, BDS, MS
Principal Investigator
Tufts University
Are You a Good Fit for This Trial?
This trial is for individuals with permanent teeth that have pulp exposure due to deep cavities, trauma, or other causes. Participants must need direct pulp capping (DPC), a procedure to preserve tooth health when the dental pulp is exposed.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Solventum™ Vitrebond™ Pulp Protect Liner/Base for direct pulp capping on permanent teeth with pulp exposure
Follow-up
Participants are monitored for pulp vitality and other dental health indicators post-restoration
What Are the Treatments Tested in This Trial?
Interventions
- Vitrebond™ Pulp Protect Liner/Base
Find a Clinic Near You
Who Is Running the Clinical Trial?
Solventum US LLC
Lead Sponsor
Bryan Hanson
Solventum US LLC
Chief Executive Officer since 2024
Bachelor's degree in Business Administration from Indiana University
Dr. Ryan Egeland
Solventum US LLC
Chief Medical Officer
MD, trained in Plastic and Reconstructive Surgery